How Oregon is tackling high drug costs.
The Oregon Division of Financial Regulation published a list of the top 25 most-expensive prescription drugs in Oregon this week.
These are the drugs that “contribute the most to annual spending by health insurance companies,” according to OregonLive.com
According to Oregon.gov, Oregon’s Prescription Drug Price Transparency Program requires health insurance companies to report on prescription drugs in Oregon. Health insurance companies reported the 25 most prescribed drugs, the 25 most costly prescription drugs, and the 25 prescription drugs which caused the biggest increases in yearly health plan spending in 2018.
Related: Drug Prices, Shortages Remain Problem
The five costliest drugs for healthcare insurance companies are:
“The cost of these newer therapies have garnered quite a bit of attention over the past several years. These drugs were approved on the premise that they provide clinical benefit for patients with serious and chronic conditions and work best when used appropriately and consistently,” says Jerry Buller, chief pharmacy officer at Trellis Rx, a health system specialty pharmacy service partner.
The high-touch specialty pharmacy service model employed by Legacy Health in Portland is an example of a health system initiative to improve adherence to these medications, which can enhance clinical outcomes and prevent disease progression (e.g., stop progression of HCV to liver cancer) or unnecessary medical events (e.g., surgery), according to Buller.
“The embedded specialty pharmacy model also serves to elevate the role of pharmacy on care teams to ensure these high-cost medications are being used appropriately and effectively,” he says.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
What States are Doing to Regulate Pharmacy Benefit Managers
March 26th 2024In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers found that state-level PBM reform focused on more transparent drug pricing, better patient access to prescription drugs, and more stringent auditing and reporting requirements.
Read More
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 26th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
Read More